You know what he's going to say ...
Remind you of this?
Tuesday, January 15, 2008
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
IN VIVO: The Business & Medicine Report
Pages
Follow Us ...
| ||||||||
Headlines from 'The Pink Sheet' DAILY
Contributors
Labels
About This Blog
Welcome to The IN VIVO Blog, home of daily commentary on recent developments in biopharmaceutical business development, R&D, financing, marketing, and policy. Join us for discussion in the comments, or contact us via email.
Click These Links!
Blog Archive
-
▼
2008
(484)
-
▼
January
(51)
- "Consensus is not our goal": A Conversation with F...
- Neuro Companies Causing Headaches
- Who's Sorry Now? Not Feeling So Good Edition
- A Mission at Risk
- Close But No Cigar
- Survey Says?! Too Little, Too Late
- The Muddy Waters of IVD
- Big Biotech M&A: Waiting for the Casus belli
- Icahn to Biogen: Take a Mulligan
- While You Were Almost Upsetting
- FDA Gets Out in Front on Vytorin, Defends LDL Endp...
- Deals of the Week: Beyond Vytoringate
- The Best Defense Is a Good Offense, Or Something L...
- Listen for the Threat of the Medicare Rebate
- J&J Tests FDA's Pain Threshold with Tapentadol
- Cardiovascular Systems Antes Up
- Vytorin: Two Sources of Angst for DTC
- Teva Buys Cogenesys
- Ventana Accepts $3.4 Billion
- Aye for an Eye
- Vytorin: In this Case, Best to Ignore History
- While You Were Losing Your Resolve
- Deals of the Week: You Can't Always Get What You Want
- Whose Life is it Anyway?
- Bio-Rad Salutes You
- Private Equity Goes Public
- The Big Winner in the Vytorin Debacle? It Might be...
- Orion to Cover Both Sides of the Atlantic
- The Man Pharma Loves to Hate
- Nissen Weighs in on ENHANCE
- Lesson from the JPMorgan Conference: Exceptions Th...
- Novo Scraps Inhaled Insulin
- At JP Morgan, Stryker's Big Smile
- Public Confidence in Drug Safety: Solution is in "...
- While You Were Staying Put
- Deals of the Week: far from the Westin St. Francis
- Amgen Braces for Another Review of EPO Safety: How...
- Biotech’s Original Sin
- The R&D Productivity Crisis: Is There a Bright Side?
- DTC User Fees Shot Down; Advertisers Face More Per...
- Iowans Fall for Obama, Will New Hampshireites?
- “We’re a Buyer, not a Seller,” Says Genzyme With I...
- The Stakes Increase on Comparative Effectiveness
- While You Were Going to California
- Regulatory Sausage Making
- Deals of the Week: New Year's Resolutions
- Another Dismal Year for New Drug Approvals
- Addex Ups Dealmaking Ante
- Congress Has Lump of Coal for FDA in Funding Bill
- New Year's Resolution 2008: Create Infrastructure ...
- The Top Ten IN VIVO Blog Posts of 2007
-
▼
January
(51)
Footer
IN VIVO: The Business & Medicine Report
© Copyright 2014 Informa plc.
Informa Business Information. All Rights Reserved.
www.pharmamedtechbi.com
No comments:
Post a Comment